TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07891780: Pharmacokinetics and Safety of a Single Dose of Epinephrine Nasal Spray in Paediatric Allergy Patients

Sponsor: Hikma Pharmaceuticals USA Inc. · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 44 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$10,384,500

Rescue Site Savings

+$6,865,500

Unlock Full NCT07891780 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07891780 Rescue Dossier →